代理品牌
Suppliers

Cell therapy
  • Facebook
  • LINE
  • Twitter
  • LinkedIn

FDA核准臨床CD34分選系統

CliniMACS CD34 Reagent System (FDA-approved)

說明
CliniMACS®CD34試劑系統已被FDA批准用於從血液中純化造血幹細胞,同時被動去除可能導致急性移植物抗宿主疾病(GVHD)的T細胞的方法。體內T細胞清除可能是降低異基因幹細胞移植AML患者GVHD發生率的可行選擇。

進一步資訊請與我們聯繫。
Description
The CliniMACS® CD34 Reagent System is an FDA-approved method for selecting hematopoietic stem cells from donor apheresis, while passively depleting T cells that can cause graft-versus-host disease (GVHD). Ex vivo T cell depletion can be a viable option to reduce GVHD incidences in patients with AML undergoing allogeneic stem cell transplantation.
Loading...
瀏覽記錄
    3詢價清單